🔎 Trials Near Me

መነሻ › የጡንቻ ካንሰር › ኔቫዳ

በኔቫዳ ለየጡንቻ ካንሰር የሚደረጉ ክሊኒካዊ ጥናቶች

ለየጡንቻ ካንሰር የሚደረጉ 19 ጥናቶች በኔቫዳ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በኔቫዳ ውስጥ ያሉ ከተሞች

Official study text (English)

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

  • Cancer Care Specialists, Reno
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 100 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05827081

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Carson Tahoe Regional Medical Center, Carson City
  • Comprehensive Cancer Centers of Nevada - Henderson, Henderson
  • Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
  • እና 25 ተጨማሪ
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  • Cancer Care Specialists, Reno
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06369285

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  • Optum Care Cancer Center ( Site 0050), Las Vegas
  • Renown Regional Medical Center ( Site 0041), Reno
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06966700

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

  • Renown Regional Medical Center, Reno
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ሴፕቴ 2026 · NCT03424005

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

  • Research Site, Reno
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 130 · ሁሉም ጾታዎች · የተሻሻለው በ8 ሴፕቴ 2026 · NCT07647328

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  • Renown Health Medical Oncology, Reno
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT06982521

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

  • Cancer Care Specialist of Reno, Reno
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ ከ18 እስከ 99 · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT07211178

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • Carson Tahoe Regional Medical Center, Carson City
  • Comprehensive Cancer Centers of Nevada - Henderson, Henderson
  • Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
  • እና 25 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 60 · ሴቶች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT05879926

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

  • Comprehensive Cancer Centers of Nevada, Las Vegas
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2026 · NCT07029399

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

  • Comprehensive Cancer Centers of Nevada, Las Vegas
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ21 ኦገስ 2026 · NCT06764940

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

  • Comprehensive Cancer Centers of Nevada, Henderson
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 100 · ሁሉም ጾታዎች · የተሻሻለው በ6 ኦገስ 2026 · NCT05232916

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  • Comprehensive Cancer Centers of Nevada, Las Vegas
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ጁን 2026 · NCT05377996

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  • Renown Regional Medical Centre, Reno
  • Cancer Care Specialists, Reno
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ጁን 2026 · NCT05696626

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  • Comprehensive Cancer Centers of Nevada, Henderson
  • Comprehensive Cancer Centers of Nevada, Henderson
  • Comprehensive Cancer Centers of Nevada, Las Vegas
  • እና 3 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ሜይ 2026 · NCT07062965

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

  • OptumCare Cancer Care at Seven Hills, Henderson
  • OptumCare Cancer Care at Charleston, Las Vegas
  • Radiation Oncology Centers of Nevada Central, Las Vegas
  • እና 8 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ50 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ23 ኤፕሪ 2026 · NCT04852887

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

  • Comprehensive Cancer Centers of Nevada, Las Vegas
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሴቶች · የተሻሻለው በ22 ኤፕሪ 2026 · NCT05683418

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • OptumCare Cancer Care at Seven Hills, Henderson
  • OptumCare Cancer Care at Charleston, Las Vegas
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ማርች 2026 · NCT06418204

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

  • Renown Regional Medical Center, Reno
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2025 · NCT05216432

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።